Haw Par Corporation Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Haw Par Corporation Limited with three other
pharmaceutical manufacturers in Asia:
Chongqing Lummy Pharmaceutical Co Ltd
sales of 990.18 million Chinese Renmimbi [US$143.71 million]
of which 98%
was Chemical Manufacturing),
Huons Global Co Ltd
of South Korea
(163.71 billion Korean Won [US$145.54 million]
of which 112%
was Pharmaceutical Department), and
Pharmally International Holding Co Ltd
based in Taiwan
(4.33 billion Taiwanese Dollars [US$143.77 million]
Haw Par Corporation Limited reported sales of 201.64 million Singapore Dollars (US$145.07 million)
December of 2016.
increase of 12.8%
versus 2015, when the company's sales were 178.83 million Singapore Dollars.
Sales at Haw Par Corporation Limited have increased during each of the previous five years
(and since 2011, sales have increased a total of 52%).
Sales of Property Rental saw an increase
24.7% in 2016, from
13.53 million Singapore Dollars to 16.87 million Singapore Dollars.
Not all segments of Haw Par Corporation Limited experienced an increase in sales in 2016:
sales of Leisure Products and Services fell 34.2% to 8.39 million Singapore Dollars.